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Abstract 
A rapid, specific and sensitive stability indicating reverse phase high performance liquid 
chromatographic method has been developed and validated for analysis of levosulpiride hydrochloride 
in both bulk and pharmaceutical dosage form. An isocratic stability indicating reversed-phase liquid 
chromatographic determination was developed for the quantitative determination of levosulpiride in 
the pharmaceutical dosage form. A sunfire C-18, 4.5µm column with mobile phase containing 
methanol-water (10:90, v/v) was used. The flow rate was 1.0 mL min-1 and effluents were monitored 
at 232 nm. The retention time of Levosulpiride was 5.5 min. Levosulpiride stock solutions were 
subjected to acid and alkali hydrolysis, chemical oxidation, wet hydrolysis, dry heat degradation and 
sun light degradation. The degraded product peaks were well resolved from the pure drug peak with 
significant difference in their retention time values. Stressed samples were assayed using developed 
LC method. The proposed method was validated with respect to linearity, accuracy, precision and 
robustness. The method was successfully applied to the estimation of Levosulpiride in tablet dosage 
forms. The proposed study describes stability indicating LC method for the estimation of 
Levosulpiride in bulk and their pharmaceutical dosage form. The method is suitable for the routine 
analysis of Levosulpiride in tablets. 
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1. Introduction 
Levosulpiride is a levo – enantiomer of racemic 
sulpiride belonging to the substituted benzamide 
group (Figure 1). It is a typical neuroleptic drug 
with sulpiride and inhibits dopaminergic D2 
receptors at the trigger zone both in central 
nervous system and in the gastrointestinal tract. 
Developed as an anti – emetic drug, sulpiride 
soon generated the interest for its antipsychotic 
properties and low potential to cause extra 
pyramidal side effect1. At low doses, sulpiride 
acts on pre-synaptic D2 receptors and increase 
dopamine turn over in dopamine terminal area2, 
this effect produces a behavioral and generalized 
motor, mental arousal, which is therapeutically 
useful in depressed patients. At high doses, 
sulpiride exert its D2 receptor blocking activity at 
both pre-synaptic and post-synaptic D2 receptor 
sites, eliciting an antipsychotic effect. 
Levosulpiride acts on central nervous at lower 
doses than needed with sulpiride. Therefore, it is 
safe to use3, 4.  Levosulpiride is a basic drug and 
has a low bioavailability5. Therefore, 
development of more effective analysis method is 
demanded for routine analysis in pharmaceutical 
dosage form. 
Several methods has been described in the 
literature, including UV – visible spectroscopy6, 
gas chromatography7, high performance liquid 
chromatography with ultraviolet, fluorescence8,9 
or mass spectrometric detection10 and chiral 
HPLC method11. There has been published 
method for estimation of levosulpiride in human 
plasma by HPLC method12. Specially, stability 
indicting RP- HPLC method is routinely used for 
analysis of levosulpiride in pharmaceutical 
dosage form as per ICH guidelines13, 14, 15, 16,  17. 
 
 
Figure 1: Chemical structure of levosulpiride 
 
2. Experimental 
2.1 Apparatus:  The liquid chromatographic 
system of waters (Calcutta, India) containing 515 
HPLC isocratic pump, variable wavelength 
programmable 2998 photodiode array detector 
and rheodyne injector with 20 µl fixed loop was 
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used. A SunFire C18 column with 250×4.6 mm 
i.d. and 5 µm particle size was used as stationary 
phase.  
2.2 Reagents and materials: Analytically pure 
levosulpiride (LSP) was procured as gratis 
sample from Sun Pharmaceutical Pvt. Ltd., 
(Baroda, India).  Methanol, water (E. Merck, 
Mumbai, India) was of LC grade and used for the 
preparation of mobile phase. Tablet formulation 
A (Volapride - 25 (25mg), Mankind pharma Ltd., 
New Delhi, India) containing labelled amount of 
25 mg of levosulpiride and tablet formulation ‘B’ 
(Nexipride – 50 (50mg), Sun pharmaceutical 
PVT Ltd., Sikkim, India) containing labelled 
amount of 50 mg of levosulpiride tablets were 
purchased from local market. 
2.3 Preparation of mobile phase and stock 
solution:  Mobile phase was prepared by 90 ml 
of water was mixed with 10 ml of methanol. The 
solution was filtered with Whatman filter paper 
No. 42 (0.45 µm). The solution was sonicated for 
15 min for degassing prior to use.  
Stock solutions were prepared by accurately 
weighing 10 mg of LSP and transferring to 10 ml 
volumetric flasks containing 3 ml of methanol. 
The flasks were sonicated for 10 minutes to 
dissolve the solids. Volumes were made up to the 
mark with methanol, which gave 1000 µg/ml. 
Aliquots from the stock solutions were 
appropriately diluted with mobile phase to obtain 
working standards of 100 µg/ml of drug.  
2.4 Chromatographic conditions:  A reversed 
phase C18 column (SunFire) equilibrated with 
mobile phase comprising of methanol: water 
(10:90) was used. Mobile phase flow rate was 
maintained at 1 ml/ min and effluent was 
monitored at 232 nm. A 20 µL of sample was 
injected using a fixed loop, and the total run time 
was 10 min. All the chromatographic separations 
were carried out at controlled room temperature 
(25 ± 2 oC).  
2. 5 Calibration curves for LSP: Appropriate 
aliquots of LSP working standard solution was 
taken in different 10 ml volumetric flasks. The 
volume was made up to the mark with mobile 
phase to obtain final concentrations of 0.1, 0.5, 1, 
5, 10 and 20 µg/ml of LSP, respectively. The 
solutions were injected using a 20 µL fixed loop 
system and chromatograms were recorded. 
Calibration curves were constructed by plotting 
peak area versus concentrations of the drug and 
regression equations was computed for LSP. 
2. 6 Analysis of Marketed Formulations: 
Twenty tablets were weighed accurately and 
finely powdered. Tablet powder equivalent to 25 
mg for tablet ‘A’ and tablet ‘B’ of LSP were 
taken in 25 ml volumetric flask. A few ml of 
methanol was added to the above flask and the 
flask was sonicated for 15 minutes. The solution 
was filtered in another 25ml volumetric flask 
using Whatman filter paper No. 42 and volume 
was made up to the mark with the same solvent.  
Appropriate volume of the aliquot was 
transferred to a 10 ml volumetric flask and the 
volume was made up to the mark with the mobile 
phase to obtain a solution containing 5 µg/ml of 
LSP. The solution was sonicated for 10 min. It 
was injected as per the above chromatographic 
conditions and peak area was recorded. The 
quantifications were carried out by keeping these 
values to the linear equation of calibration curve. 
2.7 Validation: The method was validated for 
accuracy, precision, specificity, detection limit, 
quantitation limit and robustness.  
 2.7.1 Accuracy: The accuracy of the method 
was determined by calculating recoveries of LSP 
by method of standard additions. Known amount 
of LSP (0, 2.5, 5, 7.5 µg/ml) was added to a pre 
quantified sample solutions and the amount of 
LSP was estimated by measuring the peak area 
and by fitting these values to the straight-line 
equation of calibration curve. 
2.7.2 Precision: The instrument precision was 
evaluated by injecting the solution containing 
LSP (5 µg/ml) three times repeatedly and peak 
area was measured. The results are reported in 
terms of % relative standard deviation. The intra-
day and inter-day precision study of LSP was 
carried out by estimating the corresponding 
responses 3 times on the same day and on 3 
different days (first, second and third day) for 3 
different concentrations of LSP (0.1, 5, 20 µg/ml) 
and the results are reported in terms of % relative 
standard deviation (RSD).   
2.7.3 Specificity: The specificity was estimated 
by spiking commonly used excipients (starch, talc 
and magnesium stearate) into a pre weighed 
quantity of drug. The chromatogram was taken 
by appropriate dilutions and the quantities of 
drugs were determined.  
2.7.4 Limit of detection and quantification: 
The detection limit is defined as the lowest 
concentration of an analyte that can reliably be 
differentiated from background levels. Limit of 
quantification of an individual analytical 
procedure is the lowest amount of analyte that 
can be quantitatively determined with suitable 
precision and accuracy. LOD and LOQ were 
calculated using following equation as per ICH 
guidelines. LOD = 3.3 ×σ /S and LOQ = 10 ×σ 
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/S, where σ is the standard deviation of y-
intercepts of regression lines and S is the slope of 
the calibration curve.  
2.7.5 Robustness: Robustness of the method was 
studied by deliberately changing the experimental 
conditions like flow rate, percentage of organic 
phase, and also by observing the stability of the 
sample solution at 25 ± 2° for 24 h. The sample 
solution was assayed at every 2 h interval up to 
24 h. 
2.8 Forced degradation study: Stress 
degradation study using acid and alkali 
hydrolysis, chemical oxidation, wet hydrolysis 
exposure to sun light and dry heat degradation 
was carried out and interference of the 
degradation products was investigated. LSP was 
weighed (10 mg) and transferred to 10 ml 
volumetric flasks and expose to different stress 
conditions.  
2.8.1 Alkali hydrolysis: To the 10 ml volumetric 
flask, 10 mg of LSP was taken and 2 ml of 0.1 N 
NaOH was added to perform base hydrolysis.   
The flask was heated at 80ºC for 1 week and 
allowed to cool to room temperature. Solution 
was neutralized with 0.1 N HCl and volume was 
made up to the mark with methanol. Appropriate 
aliquots was taken from the above solution and 
diluted with mobile phase to obtain final 
concentration of 10µg mL-1 of LSP.  
2.8.2 Acid hydrolysis: To the 10 ml volumetric 
flask, 10 mg of LSP was taken and 2 ml of 0.1 N 
HCl was added to perform acid hydrolysis.  The 
flask was heated at 80ºC for 1 week and allowed 
to cool to room temperature. Solution was 
neutralized with 0.1 N NaOH and volume was 
made up to the mark with methanol. Appropriate 
aliquot was taken from the above solution and 
diluted with mobile phase to obtain final 
concentration of 10µg mL-1 of LSP.  
2.8.3 Wet hydrolysis: To the 10 ml volumetric 
flask, 10 mg of LSP was taken and 2 ml of HPLC 
grade water was added to perform wet hydrolysis.  
The flask was heated at 80ºC for 1 week and 
allowed to cool to room temperature and volume 
was made up to the mark with methanol. 
Appropriate aliquot was taken from the above 
solution and diluted with mobile phase to obtain 
final concentration of 10µg mL-1 of LSP.  
2.8.4 Oxidative stress degradation: To perform 
oxidative stress degradation, 10mg of LSP was 
taken in 10 ml volumetric flask and 2 ml of 3% 
hydrogen peroxide was added. The mixture was 
heated in a water bath at 80oC for 2 h. and 
allowed to cool to room temperature and volume 
was made up to the mark with methanol. 
Appropriate aliquot was taken from above 
solution and diluted with mobile phase to obtain 
final concentration of 10 µg mL-1 of LSP.  
2.8.5 Dry heat degradation: Analytically pure 
10 mg sample of LSP was exposed in oven at 
80oC for 1 week. The solids were allowed to cool 
and transferred to volumetric flasks (10 ml) and 
dissolved in few ml of methanol. Volume was 
made up to the mark with the methanol. Solution 
was further diluted by mobile phase taking 
appropriate aliquots in 10 ml volumetric flask to 
obtain final concentration of 10 µg mL-1 of LSP. 
2.8.6 To study photolytic (sunlight) 
degradation: 10 mg of drug were exposed to 
sunlight for 1 week. The solids were allowed to 
cool and transferred to volumetric flask (10 ml) 
and dissolve in few ml of methanol. Volume was 
made up to the mark with the methanol. Solution 
was further diluted with the mobile phase taking 
appropriate aliquots in 10 ml volumetric flask to 
obtain final concentration of 10 µg mL-1 of LSP. 
All the reaction solutions were injected in the 
liquid chromatographic system and 
chromatograms were recorded. 
 
3. Results and Discussion  
3.1 Optimization of mobile phase: The 
objective of the method development was to 
resolve chromatographic peaks for active drug 
ingredients and degradation products produced 
under stressed conditions with less asymmetric 
factor.  
Various mixtures containing aqueous buffer, 
methanol, and acetonitrile were tried as mobile 
phases in the initial stage of method 
development. Mixture of methanol: water (90:10, 
v/v), methanol-water (60:40, v/v), acetonitrile-
water (50:50, v/v), were tried as mobile phase but 
satisfactory resolution of drug and degradation 
peaks were not achieved.  
The mobile phase methanol: water (10:90) was 
found to be satisfactory and gave symmetric peak 
for LSP. The retention time for proposed method 
was found to be 5.5 min as shown in Figure 2. 
The system suitability parameters like theoretical 
plates per meter and asymmetric factor for LSP 
were found to be 4805 and 0.79, respectively. 
The mobile phase flow rate was maintained at 1 
mL min-1. The UV spectra of the drug showed 
that LSP absorbed appreciably at 232 nm, so 
detection was carried out at 232 nm. 
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(B) 
Figure 2:  (A) Liquid chromatogram of LSP (RT 
5.510) (B) Liquid chromatogram of placebo on C18 
SunFire column using Methanol: Water (10:90, 
v/v) as the mobile phase 
3.2 Validation of the Proposed 
Methods 
3.2.1 Linearity: The calibration curve for LSP 
was found to be linear in the range of 0.1 - 20 µg 
mL-1 with a correlation coefficient of 0.9985. The 
standard deviation value of slope and intercept of 
LSP was found to be 1399.73 and 1499.16, 
respectively which indicated strong correlation 
between peak area and concentration. The 
regression equation of calibration curves was 
obtained as y = 47101x + 9567.5. 
3.2.2 Precision: Instrument precision was 
determined by performing injection repeatability 
test and the % RSD value for LSP was found to 
be 0.89. The intra-day and inter-day precision 
studies were carried out and the % RSD value 
was found to be 0.77 – 1.09 and 1.02 – 1.37, 
respectively. The low RSD values indicate that 
the method is precise. 
3.3.3 Accuracy: The accuracy of the method was 
determined by calculating recoveries of LSP by 
method of standard addition. The recoveries 
found to be 98.85 – 101.78 % for LSP shown in 
Table 1. The high values indicate that the method 
is accurate. 
Table 1: Accuracy study of proposed LC method 
Amount of 
Sample 
(µg/ml) 
 
Sets 
Amount drug 
of spiked 
(µg/ml) 
Area 
(n=3) 
Average amount 
recovered 
(µg/ml)
% 
Recovery 
Mean 
% 
Recovery 
% 
RSD 
 
5 
1 0 243213  
5.03 
99.21  
100.53 
 
1.48 2 0 250345 102.24 
3 0 245410 100.14 
 
5 
1 2.5 360770  
7.44 
 
99.13  
98.85 
 
0.90 2 2.5 362978 100.06 
3 2.5 356579 97.35 
 
5 
1 5 480344  
10.00 
99.90  
100.07 
 
0.64 2 5 477899 98.86 
3 5 484001 101.45 
 
5 
1 7.5 605838  
12.59 
103.19  
101.78 
 
0.59 2 7.5 598777 100.19 
3 7.5 602952 101.96 
 
3.3.4 Limit of detection and limit of 
quantification: The detection limit and 
quantitation limit for LSP was 0.1 µg mL-1 and 
0.3 µg mL-1, respectively. The above data shows 
that a nanogram quantity of the drug can be 
accurately and precisely determined.  
3.3.5 Specificity: The specificity study was 
carried out to check the interference from the 
excipients used in the formulation by preparing 
synthetic mixture containing the drug and 
excipients. The chromatogram showed peaks for 
the drug without any interfering peak. 
3.3.6 Solution stability: The solution stability 
study showed that LSP was evaluated at room 
temperature for 24 hr. The relative standard 
deviation was found below 2.0%. It showed that 
solution were stable up to 24 hrs at room 
temperature. 
3.3.7 Robustness: The method was found to be 
robust, as small but deliberate changes in the 
method parameters have no detrimental effect on 
the method performance as shown in table 2. The 
low value of relative standard deviation was 
indicating that the method was robust. 
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Table 2: Data derived from robustness of LSP for proposed LC Method 
Parameters Normal 
Condition 
Change in 
condition 
Area 
(n=3) 
% 
Recovery 
Change in % 
RSD 
 
Flow rate 
 
1.0 ml/min 
0.9 ml/min 248961.7 101.65 1.34 
1.1 ml/min 246271.6 100.45 0.95 
Mobile phase 
ratio 
Methanol : 
Water (10:90) 
(8:92) 245562.3 100.21 0.89 
(12:88) 243446.3 99.31 1.24
 
3.4 Forced degradation study: Chromatogram 
of base hydrolysis performed at 800C for 1 week 
reflux showed degradation of LSP with 
degradation product peak at retention time (RT) 
4.44 min and 12.07 min (Figure 3).  
The chromatogram of acid hydrolysis performed 
at 800C for 1 week reflux showed degradation of 
LSP with degradation product peak at retention 
time (RT) 4.64 min and 10.96 min (Figure 4). 
The chromatogram of oxidized LSP with 3% 
hydrogen peroxide at 800C for 2 h reflux showed 
degradation of LSP with degradation product 
peak at retention time (RT) 5.06 min, 14.0 min, 
22.93 min, 30.14 min and 32.34 min (Figure 5). 
The chromatogram of wet hydrolysis LSP with 
water at 800C for 1 week drug was found to be 
stable and the chromatogram of LSP with dry 
heat at 800C for 1 week showed drug was found 
to be stable. The chromatogram of LSP expose to 
sun light for 1 week showed drug was found to be 
stable  
The degradation study thereby indicated that LSP 
was found to be stable to wet hydrolysis, dry heat 
degradation study, effect of sun light while it was 
susceptible to base hydrolysis and acid hydrolysis  
and oxidation (3% hydrogen peroxide) (Table 3). 
No degradation products from different stress 
conditions affected determination of LSP.  
 
 
Figure 3: Chromatogram of 0.1M NaOH treated 
LSP at 80 0C temperature for 1 week reflux. 
 
Figure 4: Chromatogram of 0.1M HCl treated LSP 
at 80 0C temperature for 1 week reflux. 
 
Figure 5: Chromatogram of 3% H2O2 treated LSP 
at 80 0C temperature for 2 hrs reflux. 
Table 3: Data derived from forced degradation study of LSP for proposed LC method 
Condition Time  % Recovery LSP Retention time of  degradation products 
0.1 N NaOHa 1 week 0 4.43, 12.07 
0.1 N HCla 1 week 0 4.64, 10.96 
HPLC grade watera 1 week 99.92 -- 
3% H2O2a 2 hrs 4.03 14.00, 22.93, 30.14, 32.34  
Dry heata 1 week 99.51 -- 
Sun Light 1 week 98.08 -- 
asolutions were heated at 80oC for specified period of time 
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3.5 Analysis of marketed formulations: The 
proposed method was successfully applied to the 
determination of LSP in their tablet dosage form 
(Tablet A and Tablet B). The % recovery for LSP 
for tablet ‘A’ and tablet ‘B’ was found to be 
100.40 ± 1.16 and 98.66 ± 1.09 mean value ± 
standard deviation of three determinations which 
was comparable with the corresponding labeled 
amounts. 
 
Conclusion 
Proposed study describes stability indicating LC 
method for the estimation of LSP in bulk and 
their pharmaceutical dosage form. The method 
was validated and found to be simple, sensitive, 
accurate and precise. Statistical analysis proved 
that method was repeatable and selective for the 
analysis of LSP without any interference from the 
excipients. The method was successfully used for 
determination of drug in their pharmaceutical 
formulation. Also the above results indicate the 
suitability of the method for acid, base, oxidation, 
dry heat and photolytic degradation study. As the 
method separates the drugs from its degradation 
products, it can be used for analysis of stability 
samples. The method is suitable for the routine 
analysis of LSP in tablets. In addition, the HPLC 
procedure can be applied to the analysis of 
samples obtained during accelerated stability 
experiments to predict expiration dates of 
pharmaceuticals. 
 
Acknowledgements 
The authors are thankful to Sun Pharmaceuticals 
Ltd., Baroda for providing gratis sample of 
asenapine. The authors are very thankful to 
SICART and Indukaka Ipcowala College of 
pharmacy, new vallabh vidyanagar, anand, for 
providing necessary facilities to carry out 
research work. 
 
Refernces 
1. Stanley M, Rotrosen J, Martensson J, Advances in 
phycopharmacology 1982; New York: Raven 
press; 7. 
2.  Janner P, Marsden CD, Costa E, Racagni G. 
Typical and atypical antidepressant. Clinical 
practice 1982; New York: Raven press: 85. 
3. Rossi F, Forgione A. Pharmacotoxicological 
aspects of levosulpiride. Pharmacol Res. 1995; 
31(2): 81 – 94. 
4. Mucci A, Nolfe G, Maj M. Levosulpiride: a 
review of its clinical use in psychiatry. Pharmacol 
Res. 1995; 31(2): 95 – 101.  
5. Wiesel FA, Alfredsson G, Ehrnebo M, Sedvall G. 
The pharmacokinetics of intravenous and oral 
sulpiride in healthy human subjects. Eur. J. Clin. 
Pharmacol. 1980; 17(5): 385 – 391.  
6. Manjunath  S, Chouhan V, Sandeep S. 
Spectrophotometric estimation of levosulpiride in 
bulk drug and formulations. Int. J. Pharmacy and 
pharmaceutical sciences 2011; 3(2): 135 - 137. 
7. Staveris S, Jung L, Jamet G, Koffel JC. 
Quantitative  analysis  of  veralipride  in plasma  
and  urine by  gas  chromatography-mass  
spectrometry  and  gas chromatography  with  
flame-ionization  detection. J. Chromatogr. 1985; 
338: 79 – 88.  
8. Bressolle F, Bres J. Quantitative  analysis  of  
sulpiride  and  sultopride  by  high-performance  
liquid chromatography  for  pharmacokinetic  
studies. J. Chromatogr. 1985; 341: 391 – 399. 
9. Nicolas P, Fauvelle F, Ennachachibi A, Merdjan 
H, Petitjean O. Improved  determination  of  
sulpiride  in  plasma  by  ion-pair  liquid  
chromatography  with  fluorescence  detection.  J. 
Chromatogr. 1986; 381: 393 – 400. 
10. Bressolle F, Bres J, Blanchin MD, Gomeni R. 
Sulpiride pharmacokinetics in humans after 
intramuscular administration at three dose levels. 
J. Pharm. Sci. 1984; 73(8): 1128 – 1136.  
11.  Tokunaga H,    Kudo K,  Jitsufuchi N, Ohtsuka 
Y,  Imamura T. Sensitive  determination  of  
sulpiride  in  human  plasma  by  high- 
performance  liquid  chromatography. J. 
Chromatography B. 1997; 691: 203 – 207. 
12. Su-Eon Jin, Eunmi Ban, Yang-Bae Kim, Chong-
Kook Kim. Development of HPLC method for the 
determination of levosulpiride in human plasma. 
J. Pharm. Biomed. Analysis 2004; 35(4): 929-936. 
13. Topic Q1B. Photo stability Testing of New Drug 
Substances and Products. International 
Conference on Harmonization (ICH) 1996; 
Geneva: IFPMA. 
14. Topic Q2 (R1). Validation of Analytical 
Procedure; Test and Methodology. International 
Conference on Harmonization (ICH) 2005; 
Geneva. 
15. Topic Q2A. Validation of Analytical Procedures: 
Consensus Guidelines.  International Conference 
on Harmonization (ICH), 1994; Geneva. 
16. Topic Q2B. Validation of Analytical Procedures: 
Methodology, Consensus Guidelines. 
International Conference on Harmonization 
(ICH) 1996; Geneva. 
17. Topic Q1A (R2). Stability Testing of New Drug 
Substances and Products. International 
Conference on Harmonization (ICH), 2003; 
Geneva: IFPMA. 
 
